(Q41324706)

29 September 2017

title

Azelastine and flezelastine as reversing agents of multidrug resistance: pharmacological and molecular studies (English)

1 reference

29 September 2017

Azelastine and flezelastine as reversing agents of multidrug resistance: Pharmacological and molecular studies (English)

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00130-R

24 June 2024

main subject

multiple drug resistance

1 reference

1 reference

2

J. Robert

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7632160

24 June 2024

author name string

Y. P. Hu

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7632160

24 June 2024

language of work or name

English

0 references

publication date

1 July 1995

1 reference

29 September 2017

17 July 1995

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=7632160

full work available at URL

24 June 2024

https://api.elsevier.com/content/article/PII:000629529500130R?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00130-R

https://api.elsevier.com/content/article/PII:000629529500130R?httpAccept=text/plain

24 June 2024

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00130-R

24 June 2024

published in

Biochemical Pharmacology

1 reference

29 September 2017

volume

50

1 reference

29 September 2017

issue

2

1 reference

29 September 2017

page(s)

169-175

1 reference

Differentiated rat glial cell strain in tissue culture

29 September 2017

cites work

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1126/SCIENCE.161.3839.370

Charles F. Kettering Prize. P-glycoprotein and resistance to anticancer drugs

1

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00130-R

Biochemistry of multidrug resistance mediated by the multidrug transporter

24 June 2024

2

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00130-R

Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil

24 June 2024

3

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00130-R

Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro

24 June 2024

5

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00130-R

Potential usefulness of quinine to circumvent the anthracycline resistance in clinical practice

24 June 2024

6

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00130-R

Pharmacology of drugs that alter multidrug resistance in cancer

24 June 2024

7

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00130-R

Reversal of drug-resistance in multiple myeloma with verapamil.

24 June 2024

9

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00130-R

Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance

24 June 2024

10

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00130-R

Reversal of multidrug resistance by a new lipophilic cationic molecule, S9788. Comparison with 11 other MDR-modulating agents in a model of doxorubicin-resistant rat glioblastoma cells.

24 June 2024

15

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00130-R

Enhanced cytotoxicity of doxorubicin encapsulated in polyisohexylcyanoacrylate nanospheres against multidrug-resistant tumour cells in culture.

24 June 2024

16

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00130-R

Comparative cytotoxicity, DNA synthesis inhibition and drug incorporation of eight anthracyclines in a model of doxorubicin-sensitive and -resistant rat glioblastoma cells.

24 June 2024

18

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00130-R

Protein measurement with the Folin phenol reagent

24 June 2024

20

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00130-R

P-glycoprotein overexpression cannot explain the complete doxorubicin-resistance phenotype in rat glioblastoma cell lines

24 June 2024

21

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00130-R

Sequestration of doxorubicin in vesicles in a multidrug-resistant cell line (LZ-100).

24 June 2024

22

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00130-R

Does bulk damage to DNA explain the cytostatic and cytotoxic effects of topoisomerase II inhibitors?

24 June 2024

23

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00130-R

Differential over-expression of mdr1 genes in multidrug-resistant rat glioblastoma cell lines selected with doxorubicin or vincristine.

24 June 2024

24

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00130-R

Two members of the mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities

24 June 2024

25

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00130-R

24 June 2024

Identifiers

1 reference

29 September 2017

1 reference